(株)メドレックス【4586】の掲示板 2018/09/26〜2018/10/05

>>850

これね。どう読むの？

Our flagship programme, CPN 101, is a Tizanidine Patch for the management of Spasticity – a condition affecting almost 80% of patients with Multiple Sclerosis.
Some of the other conditions causing Spasticity include Spinal Cord Injury (SCI), Traumatic Brain Injury (TBI), Stroke, encephalitis, ALS etc. This is licensed from MEDRx Company Limited, Japan and is expected to be the first transdermal muscle relaxant worldwide and is expected to provide sustained efficacy, while reducing adverse events like drowsiness, dry mouth and others. The US alone has about 1.5 million cases of Spasticity that require drug treatment and result in over 60 million prescriptions.
The Company is also exploring an injectable formulation of a benzodiazepine for a rare epilepsy indication and is currently in discussions with the FDA for its development strategy. There are limited treatment options available today for this indication which are either very inconvenient or are used off-label.

>>850

ベンゾジアゼピンはメドレックスではないですよ。注射剤ですし。Annual reportを通して自社（Cipla）のことをThe companyと記載しています。